Private Markets Research Tool: What AI Must Deliver

A private markets research tool helps an investment team analyze and structure fragmented information into source-grounded findings. That definition draws a deliberate line. A database retrieves records: fund performance, deal comparables, investor allocations, company profiles. A research tool does something different. It reads the underlying evidence, extracts what matters, connects facts across documents and sources, structures the result into findings and risk items, and surfaces the inconsistencies a human reviewer should investigate. Retrieval answers the question "where is the record". Analysis answers "what does the evidence actually say, and where does it contradict itself".

The distinction matters because the retrieval side of the market keeps getting better and cheaper. S&P Global has been folding With Intelligence's private markets datasets, covering investors, fund managers and funds across private equity, private credit, hedge funds and real assets, directly into S&P Capital IQ Pro, so that a single platform can track fundraising trends, investor commitments and fund performance. When records are that easy to pull, the scarce resource is no longer access to data. It is the analyst time spent turning thousands of pages of data-room documents, management materials and market sources into a defensible view of a deal, which is why a purpose-built research system behaves differently from both a database and a general chatbot.

The four core jobs

• Extract: pull the relevant facts, figures and claims out of data-room documents, financial models, contracts and public filings, whatever their format.
• Connect: link evidence across documents and workstreams, so a revenue figure in the CIM can be checked against the model, the customer contracts and the market study.
• Structure: organize what has been extracted into findings, risk items, open questions and thematic memos that an investment committee can actually use.
• Surface: flag inconsistencies, anomalies, disclosure gaps and contradictions between sources, and route them to the right workstream before they become surprises.

A tool that only performs the first job is a search box. A tool that performs all four is a research system, and the difference shows up in the quality of the diligence that follows. The sections below set out why private markets research is structurally harder than public markets work, what an institutional-quality tool must therefore do, and how to evaluate one before it touches confidential deal material.

Public markets research starts from a standardized disclosure regime: audited filings, regulated announcements, analyst coverage and a market price that aggregates opinion continuously. Private markets research starts from nothing of the sort. The evidence for a thesis on a private company is scattered across a virtual data room, management presentations and meeting notes, financial models built by the seller's advisors, public filings and registries where they exist, market and competitor sources, transaction information on comparable deals, and the firm's own knowledge from prior deals. Each source has a different format, a different level of reliability and a different incentive behind it.

• Company materials: CIMs, management presentations, financial statements and operating KPIs, produced by the party selling the asset.
• Data-room documents: contracts, customer lists, employee data, legal and tax documentation, often thousands of files with inconsistent naming and structure.
• Public and market sources: filings, registries, market studies, competitor information and news, none of it standardized across jurisdictions.
• Transaction information: comparable deals, valuation benchmarks and exit evidence, often incomplete or lagged.
• Internal firm knowledge: prior deal experience, past diligence findings, partner and sector expertise, usually locked in individual heads and old files.

The analytical bar per deal is rising at the same time. PwC's 2026 outlook reports that global private equity transaction value reached almost $2tn in 2025, up from around $1.6tn in 2024, even as deal count fell to approximately 34,300 from about 36,500. Fewer, larger and more complex transactions mean each deal carries more capital and more scrutiny, and the evidence base behind each decision gets thinner per dollar deployed unless the research process compensates.

AI sits on both sides of this. It is a research theme, with MSCI estimating that AI-related assets now account for roughly 16% of global private equity, which makes AI exposure itself a diligence question. And it is a research tool: Deloitte's 2025 GenAI in M&A Survey of 1,000 corporate and PE leaders found that 86% of organizations have integrated generative AI into their M&A workflows. Teams that research AI-driven sectors with the same manual document process they used a decade ago are applying more capital, to more technologically complex targets, with the same analytical bandwidth.

Given that fragmentation, the capability bar for a research tool is set by the work it removes from analysts and the confidence it allows them to place in what remains. Four capabilities separate an institutional-quality system from a generic assistant.

Document analysis and evidence extraction at data-room scale

The tool should read, interpret and cross-reference thousands of documents across commercial, financial, legal, tax and technology workstreams, and extract the specific facts, figures and commitments relevant to the thesis. Extraction is not summarization. A summary tells an analyst what a document says; extraction ties each claim to the document, page and context it came from, so the finding can be verified and reused.

Source-grounded findings and cross-document comparison

Every finding should carry its source. That is what makes comparison possible: when the revenue stated in the management presentation differs from the model, or the customer concentration disclosed in one contract contradicts the CIM, the tool should surface the inconsistency rather than average it away. Cross-document comparison is where private markets research earns its keep, because contradictions between seller-produced documents are among the most reliable early signals of risk.

Thesis support, risk identification and institutional memory

The tool should structure its output around the investment thesis: which claims support it, which challenge it, which questions remain open. It should identify and evaluate risks by materiality and deal relevance rather than producing an undifferentiated list of observations. And it should connect to the firm's own institutional knowledge, so that findings, questions and evidence from prior deals inform the current one instead of leaving with the team that ran it.

Adoption patterns confirm where this value concentrates. Deloitte found that GenAI use in M&A is concentrated in pre-sign stages: 40% of adopters apply it to strategy and market assessment, followed by target identification and screening at 35% and due diligence at 35%. That is exactly the document-heavy, evidence-structuring work described above, and it is where a research tool should be judged.

A research tool earns its place in a deal process by connecting two phases that are usually run separately: the research an analyst does to form a view, and the structured diligence that validates it. The workflow below reflects the sequence practitioners report working best, starting with document-heavy, repetitive work where automation is easiest to review and keeping decision authority with the team.

• Ingest early. Connect the data room and pull public sources as soon as access is granted, so analysis starts while the seller is still populating the room rather than after.
• Extract and classify. Sort the evidence by workstream and theme: commercial, financial, legal, tax, technology, ESG. Classification is what makes the next step possible.
• Cross-reference and compare. Check figures and claims across documents, between the CIM, the model, the contracts and the market sources, and log every inconsistency with its sources.
• Surface risks and open questions. Convert inconsistencies and gaps into a risk register and a question list, ranked by materiality and deal relevance.
• Draft the outputs. Produce first drafts of thematic memos, buyer and investor questions, and IC materials, each claim traceable to its source document.
• Hand off into diligence. Pass the structured questions and risk items into the diligence workstreams, so advisors and internal experts start from hypotheses and evidence rather than from a blank page.

The last step is the one most teams skip, and it is where the research tool pays for itself. Deloitte found that 35% of GenAI adopters already apply the technology to due diligence, but the value depends on what diligence receives. A folder of PDFs is not a handoff. A ranked question list with sources attached changes the first week of diligence from document triage into hypothesis testing.

Evaluation should follow from the capability bar above. The criteria below are deliberately checkable: a vendor either demonstrates them on your documents or does not.

• Source traceability on every finding. Any AI-generated finding should link to the document, page and passage it came from. If the tool cannot show its evidence, its output cannot be verified and cannot enter an IC memo.
• Data security and confidentiality. Deal and portfolio information is among the most sensitive material a firm holds. Where data is processed, who can access it, and how it is isolated from other users' data are threshold questions, not details.
• Structured outputs. The tool should produce risk registers, evidence packs, question lists and memo drafts, not only conversational answers. Structure is what makes output reviewable and reusable.
• Honest coverage limits. A credible tool states what it has not seen. A tool that implies universal coverage of private markets information is describing a database aspiration, not a research capability.
• A clear human review point. The workflow should be built so a professional verifies findings before they influence a decision. Automation should end at a reviewable output, not at a recommendation.

The red flags are the mirror image. Watch for unsourced claims presented as findings, false precision that lends unearned confidence to thin evidence, generic chatbot behavior that treats a data room like a webpage to summarize, and any promise of guaranteed accuracy, which no system over unstructured documents can honestly make. General-purpose language models can introduce bias, contradictions and false precision into investment analysis, and a convincing but incorrect answer can distort where a team spends its diligence time.

Governance concerns are not hypothetical. In Deloitte's survey, 67% of respondents cited data security as a leading GenAI concern and 65% cited data quality and availability. For firms handling confidential deal information, those two concerns define the evaluation: the tool must protect the evidence and be honest about its quality.

Mapped against the framework above, Plausity is an AI-native due diligence and deal intelligence platform built around the research-to-diligence handoff rather than around record retrieval. Each capability corresponds to a stage of the workflow described earlier.

• Data Room Ingestion connects to virtual data rooms and scans PDFs, spreadsheets, contracts and financial models within minutes, so ingestion happens when access is granted rather than when the team gets to it.
• AI-Analysis Engine reads, interprets and cross-references thousands of documents and data points to produce due diligence analysis across commercial, financial, legal, tax and technology workstreams.
• Risk Radar identifies and evaluates findings based on materiality, financial impact, legal exposure and deal relevance, turning undifferentiated observations into a ranked risk picture.
• Report Builder drafts and structures investor-ready due diligence reports and deliverables with full source traceability, so every claim in the memo can be checked against its evidence.
• Collaboration Hub coordinates deal team activities, aligns workstreams and shares insights in real time, which is what makes the handoff into diligence workstreams a workflow rather than an email.

The division of labor is deliberate and reflects where automation delivers value in private markets: in the document-heavy preparation work around investment decisions, while humans keep decision authority. Plausity structures, extracts, connects and surfaces; the team assesses, decides and owns the conviction. That is the operating model the evidence supports, and it is the one the platform is designed for.

The framework above compresses into a checklist a deal team can apply on its next transaction. The context is a market in which 76% of PE firms report increased focus on AI, automation and data infrastructure as areas of operational focus, which means the teams you compete against are retooling this exact workflow.

• Define thesis questions before opening the data room. Write down what the investment thesis depends on and what evidence would confirm or challenge it, so ingestion is targeted rather than exploratory.
• Ingest documents early and classify them. Connect the data room on day one and sort evidence by workstream, so analysis compounds over the deal's lifetime instead of starting late.
• Require a source link on every AI-generated finding. Make traceability a hard rule: a finding without a source does not circulate, whatever tool produced it.
• Maintain a living risk register through IC preparation. Rank findings by materiality and deal relevance, update them as new documents arrive, and let the register, not memory, track what remains open.
• Verify findings against source documents before they enter the memo. Keep a human review point between AI output and anything an investment committee reads.
• Capture verified findings as reusable institutional knowledge. File what was learned, including the questions that mattered, so the next deal starts from the firm's accumulated experience rather than from zero.

The sequence matters as much as the steps. Teams that follow it remove the administrative friction from research while protecting the judgment that creates differentiated returns, and they build an institutional memory that compounds across deals. Teams that skip the review points inherit the risks of automation without its reliability.

Plausity is an AI-native due diligence and deal intelligence platform that helps M&A advisory firms, VC and PE funds, corporate development teams and investment-banking teams structure evidence, findings and questions across a data room. Plausity supports evidence extraction, source grounding, findings management and IC preparation — it does not replace human analysts, advisers or investment professionals, does not provide legal, tax, audit, regulatory or investment advice, and does not make autonomous investment decisions. All findings require human review.

To explore the underlying capabilities, see the Plausity AI analysis engine and the findings and risk intelligence product page. For team-level workflows, see how VC and PE funds and M&A advisory firms use Plausity across live deals.

1. press.spglobal.com
2. pwc.ch
3. msci.com
4. deloitte.com
5. lpgpconnect.com
6. ey.com